Nanobiotix Reports Full Phase 1 JNJ-1900 Cohort Data in Recurrent Lung Cancer

The full Phase 1 cohort has completed treatment

Nanobiotix reported complete pooled results from 24 patients with inoperable recurrent non-small cell lung cancer treated with JNJ-1900, also known as NBTXR3, plus re-irradiation in a Phase 1 study sponsored by MD Anderson. All 24 patients completed treatment and investigators reported no dose-limiting toxicities.

The company also reported no Grade 3 or higher adverse events attributed to JNJ-1900 or the injection procedure. Radiotherapy itself was associated with serious toxicity in some patients, including Grade 3 and Grade 5 events, an important distinction when interpreting the safety profile of the combination.

Sources: [1]

The study established a recommended dose for further testing

The recommended Phase 2 dose was set at an injected volume equal to 33% of gross tumor volume. JNJ-1900 is a functionalized hafnium oxide nanoparticle injected directly into a tumor and activated by radiotherapy, with the goal of increasing local energy deposition during treatment.

That mechanism is intended to enhance the local effect of radiation without functioning like a conventional systemic drug. The clinical question is whether that physical radioenhancement can improve tumor control while maintaining an acceptable treatment burden in heavily treated patients.

Sources: [1]

Early disease-control signals are encouraging but not definitive

Nanobiotix reported one-year locoregional control of 79%, one-year local progression-free survival of 61% and one-year overall survival of 70%. Median local progression-free survival was 13.6 months and median overall survival was 14.8 months in the reported cohort.

Those numbers are descriptive results from a small, early-stage study. Without a randomized comparator, they cannot establish how much benefit came from JNJ-1900 versus patient selection, re-irradiation or other factors.

Sources: [1]

Expansion data should sharpen the clinical picture

The full-cohort update matters because it moves the program beyond scattered dose-escalation observations and provides a more complete view of the treated Phase 1 population. Nanobiotix said additional enrollment is planned, which should add safety and activity data at the recommended dose.

The next analytical step is consistency. If later patients show a similar safety pattern and durable local control, the program will have a stronger basis for larger comparative development. For now, the data support continued investigation rather than a conclusion about efficacy.

Patient selection will be important when later data are compared with this cohort. Recurrent lung cancer after prior radiation is clinically difficult, and outcomes can vary with tumor location, previous treatments, performance status and the amount of disease outside the treated field. Larger studies can better show whether the local-control signal remains consistent across a broader population. They can also clarify how toxicity from repeat radiotherapy should be managed when JNJ-1900 is added to the treatment plan.

Sources: [1]